Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis

Zhenghu Chen,Long Wang,Dayong Yao,Tianshu Yang,Wen-Ming Cao,Jun Dou,Jonathan C. Pang,Shan Guan,Huiyuan Zhang,Yang Yu,Yanling Zhao,Yongfeng Wang,Xin Xu,Yan Shi,Roma Patel,Hong Zhang,Sanjeev A. Vasudevan,Shangfeng Liu,Jianhua Yang,Jed G. Nuchtern
DOI: https://doi.org/10.1038/srep38011
IF: 4.6
2016-01-01
Scientific Reports
Abstract:Neuroblastoma (NB) is the most common extracranial tumor in children. Unlike in most adult tumors, tumor suppressor protein 53 (p53) mutations occur with a relatively low frequency in NB and the downstream function of p53 is intact in NB cell lines. Wip1 is a negative regulator of p53 and hindrance of Wip1 activity by novel inhibitor GSK2830371 is a potential strategy to activate p53’s tumor suppressing function in NB. Yet, the in vivo efficacy and the possible mechanisms of GSK2830371 in NB have not yet been elucidated. Here we report that novel Wip1 inhibitor GSK2830371 induced Chk2/p53-mediated apoptosis in NB cells in a p53-dependent manner. In addition, GSK2830371 suppressed the colony-formation potential of p53 wild-type NB cell lines. Furthermore, GSK2830371 enhanced doxorubicin- (Dox) and etoposide- (VP-16) induced cytotoxicity in a subset of NB cell lines, including the chemoresistant LA-N-6 cell line. More importantly, GSK2830371 significantly inhibited tumor growth in an orthotopic xenograft NB mouse model by inducing Chk2/p53-mediated apoptosis in vivo . Taken together, this study suggests that GSK2830371 induces Chk2/p53-mediated apoptosis both in vitro and in vivo in a p53 dependent manner.
What problem does this paper attempt to address?